BIOLOGICAL PREPARATIONS IN THERAPY OF INFLAMMATORY BOWEL DISEASES: REALITY AND PROSPECTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The etiology of inflammatory bowel diseases (IBDs) is unknown, and pathogenesis is not fully understood. To date, monoclonal antibodies to tumor necrosis factor a and antibodies to α4-β7 are available for patients with IBDs in the Russian Federation. But at present, the direction of targeted therapy is actively developing in the world: the experience of the use of these agents is accumulating; the search for new molecules that are capable of interrupting the inflammatory cascade and simultaneously having a high safety profile is continuing.

Full Text

Restricted Access

About the authors

M. I Skalinskaya

FSBEI HE NWSMU n.a. I.I. Mechnikov

Email: mskalinskaya@yahoo.com
PhD in Medical Sciences, Associate Professor at the Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietology

I. G Bakulin

FSBEI HE NWSMU n.a. I.I. Mechnikov

E. V Skazyvaeva

FSBEI HE NWSMU n.a. I.I. Mechnikov

T. N Zhigalova

FSBEI HE NWSMU n.a. I.I. Mechnikov

K. N Ryndin

FSBEI HE NWSMU n.a. I.I. Mechnikov

M. V Solovyev

FSBMEI HE «Military Medical Academy n.a. S.M. Kirov» of the Ministry of Defense of the Russian Federation

References

  1. Neurath M.F., Fuss I., Kelsall B.L., Presky D.H., Waegell W., Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J. Exp. Med. 1996;183(6):2605-16.
  2. Monteleone G., Boirivant M., Pallone F., MacDonald T.T. TGF-β1 and Smad7 in the regulation of IBD. Mucosal. Immunol. 2008;1(1):50-3.
  3. Ito R., Shin-Ya M., Kishida T., Urano A., Takada R., Sakagami J., Imanishi J., Kita M., Ueda Y., Iwakura Y., Kataoka K., Okanoue T., Mazda O. Interferongamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 2006;146(2):330-38.
  4. Roggenbuck D., Reinhold D., Wex T., Goihl A., von Arnim U., Malfertheiner P., B ttnerT., Porstmann T., Porstmann S., Liedvogel B., Bogdanos D.P., Laass M.W, Conrad K. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clin. Chim. Acta. 2011;412(9-10):718-24.
  5. Muzes G., Molnár B., Tulassay Z., Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J. Gastroenterol. 2012;18(41):5848-61.
  6. Geremia A., Jewell D.P. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 2012;6:223-37.
  7. Lu Y.C., Yeh W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine. 2008; 42:145-51.
  8. Coskun M., Olsen J., Seidelin J.B., Nielsen O.H. MAP kinases in inflammatory bowel disease. Clin. Chim. Acta. 2011;412:513-20.
  9. Белоусова Е.А., Морозова Н.А., Никитина Н.В. Инфликсимаб (ремикейд) в лечении рефрактерных форм болезни Крона. РМЖ. 2005;7(1):28-32.
  10. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P. Maintenanse Infliximab for Crohn's Disease: the ACCENT I Randomised Trial. Lancet. 2002;359:1541-49.
  11. Rutgeerts P.A. Critical Assessment of new Therapies in Inflammatory Bovel Diseases. J. Gastroenterol. Hepatol. 2002;17:177.
  12. Rutgeerts P., Feagan B., Olson A., et al. A Randomized Placebo-Controlled Trial of Infliximab Therapy for Active Ulcerative Colitis: Act 1 Trial. Gastroenterol. 2005;128(Suppl. 2).
  13. Sandborn W., Rachmilewitz D., Hanauer S., et al. Infliximab Induction and Maintenanse Therapy for Ulcerative Colitis: the Act 2 Trial. Gastroenterol. 2005;128(4, Suppl. 2):49.
  14. Argüelles-Arias F., Guerra Veloz M.F., Perea Amarillo R., Vilches-Arenas A., Castro Laria L., Maldonado Pérez B., Chaaro D., Benítez Roldán A., Merino V., Ramírez G., Caunedo Álvarez A., Romero Gómez M. Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months. Dig. Dis. Sci. 2017;62(5):1305-12.
  15. Jorgensen K.K., Olsen I.C., Goll G.L., Lorentzen M., Bolstad N., Haavardsholm E.A., Lundin K.E.A., Mork C., Jahnsen J., Kvien T.K. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304-16.
  16. Udata C., Hua S.Y., Yin D., et al. A phase I pharmacokinetics trial comparing PF-06438179 (a potential biosimilar) and infliximab in healthy volunteers (REFLEXTIONS B537-01). Ann. Rheum. Dis. 2014;73:494.
  17. Shin D., Kim Y.H., Kim Y.S., Fuhr R., Körnicke T. A phase I pharmacokinetic study comparing SB2, an infliximab biosimilar, and infliximab reference product (Remicade) in healthy subjects [abstract.]. Ann. Rheum. Dis. 2015; 74(suppl 2):459-60.
  18. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., Panaccione R., Wolf D., Pollack P. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323-33.
  19. Yang Z., Ye X.Q., Zhu Y.Z., Liu Z., Zou Y., Deng Y., Guo C.C., Garg S.K., Feng J.S. Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis. Int. J. Clin. Exp. Med. 2015;8(1):86-93.
  20. Papp K., Bachelez H., Costanzo A., Foley P., Gooderham M., Kaur P., Philipp S., Spelman L., Zhang N., Strober B. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol. 2017;76(6):1093.
  21. Kaur P., Chow V., Zhang N., Moxness M., Kaliyaperumal A., Markus R. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann. Rheum. Dis. 2017;76(3):526-33.
  22. Lowenberg M., de Boer N.K., Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clin. Exp. Gastroenterol. 2014;7:53-9.
  23. Tursi A., Allegretta L., Buccianti N., Della Valle N., Elisei W., Forti G., Faggiani R., Gallina S., Hadad Y., Larussa T., Lauria A., Luzza F., Lorenzetti R., Mocci G., Penna A., Polimeni N., Pranzo G., Ricciardelli C., Zampaletta C., Picchio M. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers. J Gastrointestin Liver Dis. 2017;26(3): 239-44.
  24. Voulgari P.V. Emerging drugs for rheumatoid arthritis. Expert Opin. Emerging Drugs. 2008;13:175-96.
  25. Ruiz Garcia V., Jobanputra P., Burls A., et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. The Cochrane database of systematic reviews 9. MAbs. 2010; 2(2):137-47.
  26. Lee S.D., Rubin D.T., Sandborn W.J., Randall C., Younes Z., Schreiber S., Schwartz D.A., Burakoff R., Binion D., Dassopoulos T., Arsenescu R., Gutierrez A., Scherl E., Kayhan C., Hasan I., Kosutic G., Spearman M., Sen D., Coarse J., Hanauer S. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016;22(8):1870-80.
  27. Rutgeerts P., Fedorak R., Rachmilevich D., et al. Onercept (Recombinant Human P55 Tumour Necrosis Factor Receptor) Treatment in Patients with Active Crohn's Disease: Randomized, Placebo-Controlled, Dose-Finding Phase II Study. Gut. 2004;53(Suppl. VI.):12
  28. Travis S., Yap L.M., Hawkey C., Warren B., Lazarov M., Fong T., Tesi R.J. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel. Dis. 2005; 11(8):713-19.
  29. Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S., Natarajan A., Lee S., Plavina T., Scanlon J.V., Sandrock A., Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2012;366:1870-80.
  30. Feagan B.G., Rutgeerts P., Sands B.E., Hanauer S., Colombel J.F., Sandborn W.J., Van Assche G., Axler J., Kim H.J., Danese S., Fox I., Milch C., Sankoh S., Wyant T., Xu J., Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2013;369:699-710.
  31. Sandborn W.J., Feagan B.G., Rutgeerts P, Hanauer S., Colombel J.F., Sands B.E., Lukas M., Fedorak R.N., Lee S., Bressler B., Fox I., Rosario M., Sankoh S., Xu J., Stephens K., Milch C., Parikh A. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2013;369:711-21.
  32. Sands B.E., Feagan B.G., Rutgeerts P., Colombe lJ.F., Sandborn W.J., Sy R., D'Haens G., Ben-Horin S., Xu J., Rosario M., Fox I., Parikh A., Milch C., Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618-27.
  33. Jin Y., Lin Y., Lin L.J., Zheng C.Q. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J. Gastroenterol. 2015;21(20):6352-60.
  34. Amiot A., Grimaud J.C., Peyrin-Biroulet L., et al. Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2016;14(11):1593-601.
  35. Vermeire S., O'Byrne S., Keir M., Williams M., Lu T.T., Mansfield J.C., Lamb C.A., Feagan B.G., Panes J., Salas A., Baumgart D.C., Schreiber S., Dotan I., Sandborn W.J., Tew G.W., Luca D., Tang M.T., Diehl L., Eastham-Anderson J., De Hertogh G., Perrier C., Egen J.G., Kirby J.A., van Assche G., Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384:309-18.
  36. Lin L., Liu X., Wang D., Zheng C. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(10):e556.
  37. Vermeire S., Sandborn W.J., Danese S., Hébuterne X., Salzberg B.A., Klopocka M., Tarabar D., Vanasek T., Gregus M., Hellstern P.A., Kim J.S., Sparrow M.P., Gorelick K.J., Hinz M., Ahmad A., Pradhan V., Hassan-Zahraee M., Clare R., Cataldi F., Reinisch W. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10090):135-44.
  38. Namour F., Galien R., Van Kaem T., Van der Aa A., Vanhoutte F., Beetens J., Van't Klooster G. Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. Br. J. Clin. Pharmacol. 2016;82(1):139-48.
  39. D'Haens G., Vermeire S., Vogelsang H., Allez M., Desreumaux P., Van Gossum A., Sandborn W.J., Baumgart D.C., Ransohoff R.M., Comer G.M., Ahmad A., Cataldi F., Cheng J., Clare R., Gorelick K.J., Kaminski A., Pradhan V., Rivers S., Sikpi M.O., Zhang Y., Hassan-Zahraee M., Reinisch W., Stuve O. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study: MADCAM-1Antibody and CNS Immune Surveillance. J. Crohns Colitis. 2017;1:1-9.
  40. IBD News Today/ [Электронный ресурс]. IBD News Today, 2013-2017 URL: https:// ibdnewstoday.com/ozanimod-rpc-1063/ (Дата обращения 01.10.2017).
  41. Keshav S., Vañásek T., Niv Y., Petryka R., Howaldt S., Bafutto M., Rácz I., Hetzel D., Nielsen O.H., Vermeire S., Reinisch W., Karién P., Schreiber S., Schall T.J., Bekker P. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One. 2013;8:e60094.
  42. Feagan B.G., Sandborn W.J., D'Haens G., Lee S.D., Allez M., Fedorak R.N., Seidler U., Vermeire S., Lawrance I.C., Maroney A.C., Jurgensen C.H., Heath A., Chang D.J. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Aliment. Pharmacol. Ther. 2015;42(10): 1170-81.
  43. Cătană C.S., Berindan Neagoe I., Cozma V., Magdaş C., Tăbăran F, Dumitraşcu D.L. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 2015;21(19):5823-30. Published online 2015 May 21.
  44. MacDonald J.K., Nguyen T.M., Khanna R., Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2016.
  45. Yoshida H., Kimura A., Fukaya T., Sekiya T. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochem. Biophys. Res. Commun. 2012;418:234-40.
  46. Sandborn W.J., Su C., Sands B.E., D'Haens G.R., Vermeire S., Schreiber S., Danese S., Feagan B.G., Reinisch W., Niezychowski W., Friedman G., Lawendy N., Yu D., Woodworth D., Mukherjee A., Zhang H., Healey P., Panés J. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2017;376(18):1723-36.
  47. Sandborn W.J., Ghosh S., Panes J., Vranic I., Su C., Rousell S., Niezychowski W. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 2012;367:616-24.
  48. Panés J., Sandborn WJ, Schreiber S., Sands B.E., Vermeire S., D'Haens G., Panaccione R., Higgins P.D.R., Colombel J.F, Feagan B.G., Chan G., Moscariello M., Wang W., Niezychowski W., Marren A., Healey P., Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomized placebo-controlled trials. Gut. 2017;66(6):1049-59.
  49. Herrlinger K.R., Diculescu M., Fellermann K., Hartmann H., Howaldt S., Nikolov R., Petrov A., Reindl W., Otte J.M., Stoynov S., Strauch U., Sturm A., Voiosu R., Ammendola A., Dietrich B., Hentsch B., Stange E.F. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study. J. Crohn's Colitis. 2013;7(8): 636-43.
  50. Comi G., Jeffery D., Kappos L., Montalban X., Boyko A., Rocca M.A., Filippi M. Placebocontrolled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 2012;366:1000-9.
  51. D'Haens G., Sandborn W.J., Colombel J.F., et al. A phase II study of laquinimod in Crohn's disease. The small molecule laquinimod was analyzed in a dose escalation induction study in CD showing clinically efficacy versus placebo. Gut. 2015 Aug;64(8):1227-35.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies